UJ9 - Shandong Boan Biotechnology Co., Ltd. (DB) - Share Price and News

Shandong Boan Biotechnology Co., Ltd.
DE ˙ DB
1,33 € ↓ -0.09 (-6.34%)
2025-09-04
SHARE PRICE
Overview
Shandong Boan Biotechnology Co., Ltd. is based in China and operates primarily within the biotechnology industry, focusing on the research, development, and manufacturing of biochemical products derived from corn processing. A notable aspect of its business involves producing and supplying vital intermediates for various industrial applications, particularly in sectors like pharmaceuticals, food and beverage, and bioengineering. The company is recognized for its commitment to innovation in bio-based technologies, notably exemplified by its development of eco-friendly processes for producing amino acids and their derivatives. Shandong Boan leverages cutting-edge fermentation technology, which underscores its strategic emphasis on sustainable production methods that align with global environmental standards.
Basic Stats

The share price of Shandong Boan Biotechnology Co., Ltd. as of 4 September 2025 is 1,33 € / share. This is a decrease of -8.28% from the prior week. The market cap (or net worth) of Shandong Boan Biotechnology Co., Ltd. as of 5 September 2025 is 763,86 € MM.

The Factor Analysis chart (below right) shows a view of Shandong Boan Biotechnology Co., Ltd. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.

For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.

Market Cap 763.86 MM
EV
Shares Out. 574.33 MM
Earnings Date
EPS (TTM) 0.06
Dividend Yield
Ex-Dividend Date
Borrow Rate
Short Shares Avail.
Short Interest
Short Float
Days to Cover
Risk Free Rate 4.17 %
Price Change (1 yr) 33.00 %
Volatility (1 yr) 0.74
Beta 0.09
Sharpe Ratio (1 yr) 0.39
Sortino Ratio (1 yr) 0.78
PE Ratio
Price/Book
Price/TBV
Book/Market
EBIT/EV
EBIT(3yr avg)/EV
ROA 0.01
ROE 0.02
ROIC 0.01
CROIC -0.00
OCROIC -0.04
Implied Volatility
Put/Call OI Ratio
Growth 52.95 /100
Profitability 33.83 /100
Quality Score 33.43 /100
Value Score
Momentum Score 50.22 /100
Stability (Low Vol) Score 21.10 /100
Analyst Sentiment
Fund Sentiment
Insider Sentiment
Officer Sentiment
Dividend Score
QVM Score
Piotroski F-SCORE 4.00 /9
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for Shandong Boan Biotechnology Co., Ltd.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Date Analyst Prior Latest
Recommendation
Action
No data available.
Other Listings
HK:6955 13,31 HK$
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista